source
- RNAi developers see surge in IPOs and funding as industry interest revivesBioPharma Dive’s latest data‑visualization series highlights a rapid rise in interest and investment for companies developing RNA interference (RNAi) medicines. After a years‑long lull, more than…
- Roche signs up to $813M deal with Zymeworks for preclinical trispecific T cell engagerRoche announced a partnership with Zymeworks that includes an upfront payment of $55 million for worldwide rights to a trispecific T cell engager currently in preclinical development. The agreemen…